Cargando…
Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of e...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818008/ https://www.ncbi.nlm.nih.gov/pubmed/33521289 http://dx.doi.org/10.1177/2381468320978407 |
_version_ | 1783638751326502912 |
---|---|
author | Hauber, Brett Mange, Brennan Zhou, Mo Chaudhuri, Shomesh Benz, Heather L. Caldwell, Brittany Ruiz, John P. Saha, Anindita Ho, Martin Christopher, Stephanie Bardot, Dawn Sheehan, Margaret Donnelly, Anne McLaughlin, Lauren Gwinn, Katrina Lo, Andrew Sheldon, Murray |
author_facet | Hauber, Brett Mange, Brennan Zhou, Mo Chaudhuri, Shomesh Benz, Heather L. Caldwell, Brittany Ruiz, John P. Saha, Anindita Ho, Martin Christopher, Stephanie Bardot, Dawn Sheehan, Margaret Donnelly, Anne McLaughlin, Lauren Gwinn, Katrina Lo, Andrew Sheldon, Murray |
author_sort | Hauber, Brett |
collection | PubMed |
description | Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. Methods. We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients’ risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in “on-time,” motor symptoms, pain, cognition, and pill burden. The survey elicited patients’ willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. Results. A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. Conclusions. PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices. |
format | Online Article Text |
id | pubmed-7818008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-78180082021-01-28 Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study Hauber, Brett Mange, Brennan Zhou, Mo Chaudhuri, Shomesh Benz, Heather L. Caldwell, Brittany Ruiz, John P. Saha, Anindita Ho, Martin Christopher, Stephanie Bardot, Dawn Sheehan, Margaret Donnelly, Anne McLaughlin, Lauren Gwinn, Katrina Lo, Andrew Sheldon, Murray MDM Policy Pract Article Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. Methods. We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients’ risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in “on-time,” motor symptoms, pain, cognition, and pill burden. The survey elicited patients’ willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. Results. A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. Conclusions. PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices. SAGE Publications 2021-01-18 /pmc/articles/PMC7818008/ /pubmed/33521289 http://dx.doi.org/10.1177/2381468320978407 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Article Hauber, Brett Mange, Brennan Zhou, Mo Chaudhuri, Shomesh Benz, Heather L. Caldwell, Brittany Ruiz, John P. Saha, Anindita Ho, Martin Christopher, Stephanie Bardot, Dawn Sheehan, Margaret Donnelly, Anne McLaughlin, Lauren Gwinn, Katrina Lo, Andrew Sheldon, Murray Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study |
title | Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for
Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered
Threshold Technique Study |
title_full | Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for
Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered
Threshold Technique Study |
title_fullStr | Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for
Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered
Threshold Technique Study |
title_full_unstemmed | Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for
Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered
Threshold Technique Study |
title_short | Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for
Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered
Threshold Technique Study |
title_sort | parkinson’s patients’ tolerance for risk and willingness to wait for
potential benefits of novel neurostimulation devices: a patient-centered
threshold technique study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818008/ https://www.ncbi.nlm.nih.gov/pubmed/33521289 http://dx.doi.org/10.1177/2381468320978407 |
work_keys_str_mv | AT hauberbrett parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT mangebrennan parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT zhoumo parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT chaudhurishomesh parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT benzheatherl parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT caldwellbrittany parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT ruizjohnp parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT sahaanindita parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT homartin parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT christopherstephanie parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT bardotdawn parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT sheehanmargaret parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT donnellyanne parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT mclaughlinlauren parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT gwinnkatrina parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT loandrew parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy AT sheldonmurray parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy |